Verastem Inc.

10/09/2024 | Press release | Distributed by Public on 10/09/2024 04:22

Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.